# Lupin (NSE: LUPIN) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/LUPIN · Pivot · prices to 21 Oct 2026

Lupin (NSE: LUPIN) closed at ₹1,942.00 on 21 Oct 2026. With a market capitalisation of ₹88,246 Cr, it ranks 124th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 16.6× trailing earnings, against a return on equity of 23.8% in FY26. Over the past year the share price has fallen 1.5%. Its 52-week range is ₹1,900.00 (28 Oct 2025) to ₹2,529.50 (16 Jul 2026); the last close is 23.2% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹5,755 Cr (+17.8% year on year) and net profit ₹528 Cr (+27.0%), on a consolidated basis. Promoters held 46.85% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,942.00 |
| Market cap | ₹88,246 Cr |
| P/E (trailing) | 16.6 |
| ROE | 23.8% (FY26) |
| ROCE | 30.6% (FY26) |
| Debt to equity | 0.26 |
| 52-week high | ₹2,529.50 (16 Jul 2026) |
| 52-week low | ₹1,900.00 (28 Oct 2025) |
| 1-year return | −1.5% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹5,755 Cr | +17.8% | ₹528 Cr | +27.0% | ₹9.73 |
| Q4 FY26 | ₹5,028 Cr | +19.2% | ₹429 Cr | +37.2% | ₹11.26 |
| Q3 FY26 | ₹5,345 Cr | +14.8% | ₹498 Cr | +5.9% | ₹14.42 |
| Q2 FY26 | ₹4,818 Cr | +15.9% | ₹375 Cr | +13.7% | ₹10.60 |
| Q1 FY26 | ₹4,883 Cr | +19.0% | ₹415 Cr | +23.8% | ₹12.09 |
| Q4 FY25 | ₹4,217 Cr | +27.9% | ₹313 Cr | −53.3% | ₹8.95 |
| Q3 FY25 | ₹4,657 Cr | +34.3% | ₹470 Cr | +37.9% | ₹13.99 |
| Q2 FY25 | ₹4,157 Cr | +39.4% | ₹329 Cr | +62.5% | ₹9.53 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹22,708 Cr | ₹3,306 Cr |
| FY24 | ₹20,011 Cr | ₹1,936 Cr |
| FY23 | ₹16,642 Cr | ₹448 Cr |
| FY22 | ₹16,405 Cr | −₹1,510 Cr |
| FY21 | ₹15,163 Cr | ₹1,227 Cr |
| FY20 | ₹15,375 Cr | −₹274 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 46.85%
- Foreign institutions: 22.42%
- Domestic institutions: 24.65%
- Non-institutions: 6.08%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Apollo Hospitals Enterprise](https://app.pivotnow.in/stock/APOLLOHOSP) | ₹7,695.00 | ₹1,10,642 Cr | 57 | — |
| [Cipla](https://app.pivotnow.in/stock/CIPLA) | ₹1,324.00 | ₹1,06,959 Cr | 27.5 | — |
| [Dr. Reddy's Laboratories](https://app.pivotnow.in/stock/DRREDDY) | ₹1,241.20 | ₹1,03,600 Cr | — | — |
| [Aurobindo Pharma](https://app.pivotnow.in/stock/AUROPHARMA) | ₹1,617.00 | ₹93,039 Cr | 26.8 | — |
| [Mankind Pharma](https://app.pivotnow.in/stock/MANKIND) | ₹2,251.00 | ₹92,965 Cr | 48.7 | — |
| [Max Healthcare Institute](https://app.pivotnow.in/stock/MAXHEALTH) | ₹830.00 | ₹80,779 Cr | 56.3 | — |

## Questions and answers

### What is the share price of Lupin today?

Lupin (NSE: LUPIN) last closed at ₹1,942.00 on 21 Oct 2026. Its 52-week high is ₹2,529.50 and its 52-week low is ₹1,900.00.

### What is the market cap of Lupin?

Lupin's market capitalisation is ₹88,246 Cr (₹88,246 Cr) at the 19 Oct 2026 close, ranking 124th among the NSE companies Pivot tracks.

### What is the P/E ratio of Lupin?

Lupin trades at a trailing P/E of 16.6. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 48.7.

### What is the ROE and ROCE of Lupin?

Return on equity was 23.8% in FY26 and return on capital employed was 30.6% in FY26 (consolidated figures).

### Is Lupin a debt-free company?

No. Lupin's debt-to-equity ratio was 0.26 in FY26, with total debt of ₹1,643 Cr.

### What were Lupin's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Lupin reported revenue of ₹5,755 Cr, +17.8% year on year, and net profit of ₹528 Cr, +27.0% year on year.

### How has Lupin stock performed over the last year?

Lupin's share price has fallen 1.5% over the past year, −22.4% over three months and −7.6% over one month, to the 19 Oct 2026 close.

### What is the shareholding pattern of Lupin?

As of 30 Jun 2026: promoters 46.85%, foreign institutions 22.42%, domestic institutions 24.65%, non-institutions 6.08%.

### Who are Lupin's competitors?

The listed Pharma & Healthcare companies closest to Lupin by market cap are Apollo Hospitals Enterprise, Cipla, Dr. Reddy's Laboratories, Aurobindo Pharma, Mankind Pharma and Max Healthcare Institute.

### Is Lupin a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Lupin's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on LUPIN against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.